Dihydroergotamine Injection
Dihydroergotamine Injection is an ergot-type medicine used to stop migraine attacks and cluster headaches once they have started.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 8 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Dihydroergotamine Injection is a decades-old ergot medicine, available generically, that stops migraine and cluster headache attacks in adults by acting on serotonin receptors to narrow blood vessels around the brain and calm pain nerves, usually after triptans have failed. An occasional dose is usually well tolerated, with flushing, dizziness, tingling and diarrhea the common complaints. Its boxed warning forbids strong CYP3A4 blockers (drugs that slow its breakdown), such as clarithromycin, erythromycin, ritonavir or ketoconazole, because levels rise and blood vessels can clamp down, cutting off blood flow to the brain, fingers or toes. Use it for attacks only, never for prevention or daily, and only after a heart check.
Clinical pearls
- Keep sumatriptan and other triptans, and any other ergot medicine, at least 24 hours away from a dose.
- Grapefruit juice, fluconazole and fluoxetine can also raise its levels, so mention them before using it.
- Nicotine from smoking, vaping or patches narrows blood vessels further and adds to the risk of poor circulation.
- Avoid it in pregnancy, and pump and discard breast milk during treatment and for 3 days after the last dose.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Do not use dihydroergotamine with strong CYP3A4 inhibitors. These include certain HIV medicines (protease inhibitors) and macrolide antibiotics. They raise dihydroergotamine levels in the blood.
Higher levels can cause severe blood vessel spasm, cutting off blood flow to the brain or to the arms and legs. This can be serious or life-threatening. Warning signs include cold, numb, pale, or bluish fingers or toes, and stroke symptoms. Always tell your prescriber and pharmacist about every medicine you take.
Patient information guide A plain-language walkthrough of Dihydroergotamine Injection, written from its FDA label.
What Dihydroergotamine Injection is used for
▾
Dihydroergotamine Injection is used to treat headache attacks in adults.
- Acute treatment of migraine with or without aura (Brekiya).
- Acute treatment of cluster headaches (Brekiya).
- Brekiya is not approved for migraine prevention, hemiplegic migraine, or migraine with brainstem aura.
How Dihydroergotamine Injection works
▾
Dihydroergotamine binds strongly to serotonin receptors, especially 5-HT1D. It also binds to other serotonin, noradrenaline, and dopamine receptors.
Its migraine relief is thought to come from narrowing blood vessels inside the head and from calming pain nerves that release inflammatory chemicals. It also has oxytocic properties, meaning it can stimulate the uterus.
Dihydroergotamine Injection dosage
▾
Brekiya is a single-dose autoinjector given under the skin of the middle thigh when a headache attack occurs. If needed, the dose may be repeated after an hour, within daily and weekly maximums on the label. Do not use it daily over the long term.
- Rotate sites and stay at least 2 inches from your last injection.
- Check that the liquid is clear and colorless.
- The injection takes about 10 seconds. The window turns fully blue when the dose is done.
Follow your prescriber's directions and the Instructions for Use.
Dosing details from the FDA-approved label
From the Dihydroergotamine Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Acute treatment (BREKIYA autoinjector, subcutaneous injection only)
- 1 mg administered subcutaneously via a single 1 mL autoinjector
- The dose may be repeated, as needed, at 1-hour intervals
- Maximum: Do not exceed 3 mg (3 doses) in a 24-hour period; do not exceed 6 mg (6 doses) total in a week
- Cardiovascular evaluation recommended before first dose; for patients with risk factors predictive of coronary artery disease, first dose strongly recommended in an equipped healthcare facility
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION For subcutaneous injection only. ( 2.1 ) Recommended dosage is 1 mg administered subcutaneously as a single 1 mL autoinjector. ( 2.1 ) Do not exceed 3 mg (3 doses) in a 24-hour period. ( 2.1 ) Do not exceed 6 mg (6 doses) in a week. ( 2.1 ) Prior to initiation, a cardiovascular evaluation is recommended. ( 2.2 ) 2.1 Recommended Dosage BREKIYA autoinjector is for subcutaneous injection only. The recommended dose of BREKIYA is 1 mg administered subcutaneously via a single 1 mL autoinjector. The dose may be repeated, as needed, at 1-hour intervals to a total maximum of 3 mg (3 doses) in a 24-hour period. Do not exceed 6 mg (6 doses) total in a week. 2.2 Assessment Prior to First Dose Prior to initiation of BREKIYA, a cardiovascular evaluation is recommended [see Warnings and Precautions (5.3) ] . For patients with risk factors predictive of coronary artery disease who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of BREKIYA take place in the setting of an equipped healthcare facility. 2.3 Important Administration Instructions See the “Instructions for Use” for detailed steps for administering the subcutaneous injection using the autoinjector. Preparation BREKIYA is a prefilled, single-dose disposable autoinjector intended to be given subcutaneously into the skin of the middle thigh. Rotate injection sites. Choose an injection site at least 2 inches away from the last injection site. Do not inject into moles, scars, birthmarks, or areas where the skin is tender, bruised, red, or hard. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Carefully examine the liquid medication for discoloration, cloudiness, floating flakes or particles. Administer only if clear and colorless. Administration Remove the red needle cap by pulling it straight off. Position the autoinjector straight onto the cleaned injection site with the white safety guard resting on the skin. Push the autoinjector down and press and release the gray activation button to start the injection. A “click” will sound when the injection starts.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Dihydroergotamine Injection side effects
▾
Reported side effects include:
Common side effects
- Dizziness
- Headache
- Flushing
- Diarrhea
- Rash
- Increased sweating
- Anxiety
- Tingling or numbness (paresthesia)
When to get medical help
- Get emergency help for chest pain, a racing or irregular heartbeat, or shortness of breath. These can signal a heart attack or a dangerous heart rhythm.
- Get emergency help for signs of stroke or brain bleeding, such as sudden severe headache, weakness, or trouble speaking.
- Stop the medicine and call your provider if your fingers or toes feel cold, numb, pale, or bluish, or if you have muscle pains. These can signal narrowed blood vessels.
- Call your provider if you have severe stomach pain or other signs of reduced blood flow, such as ischemic bowel syndrome or Raynaud's syndrome.
- Call your provider if you develop very high blood pressure.
- Tell your provider if you have headaches on most days after using migraine medicines 10 or more days a month. This may be medication overuse headache.
- Call your provider about persistent breathlessness, back or flank pain, or other problems after long daily use. Fibrosis (scar-like tissue buildup) has been reported with prolonged daily use.
Dihydroergotamine Injection warnings and precautions
▾
- Strong CYP3A4 inhibitors: boxed warning for severe reduced blood flow.
- Heart risks: heart attack, dangerous rhythms, and coronary artery spasm, some fatal.
- Brain risks: stroke and brain bleeding have been reported.
- Vasospasm: can cause gangrene in people with poor circulation.
- Blood pressure: can rise significantly.
- Overuse: medication overuse headache and fibrosis with prolonged daily use.
- Pregnancy: may cause preterm labor.
Dihydroergotamine Injection interactions
▾
Several medicines can make dihydroergotamine dangerous.
- Strong CYP3A4 inhibitors (such as ritonavir, clarithromycin, ketoconazole): contraindicated because of dangerous blood vessel spasm.
- Moderate or weaker CYP3A4 inhibitors, including grapefruit juice: use with caution.
- Triptans, other ergot medicines, and methysergide: not within 24 hours of each other because of additive vessel narrowing.
- Vasoconstrictors: contraindicated because blood pressure can spike.
- Beta blockers and nicotine: may worsen vessel narrowing.
- SSRIs: rare weakness, overactive reflexes, and poor coordination.
Interactions listed in the FDA-approved label
From the Dihydroergotamine Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP3A4 inhibitors: Rare serious adverse events with intravenous dihydroergotamine and strong CYP3A4 inhibitors resulted in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. Use with BREKIYA is contraindicated.
- Moderate CYP3A4 inhibitors: The label groups these with CYP3A4 inhibitors that may raise the risk of serious vasospastic adverse events. Administer with caution.
- Triptans (5-HT1B/1D receptor agonists): Triptans have been reported to cause coronary artery vasospasm, and the effect could be additive with BREKIYA. Triptans and BREKIYA should not be taken within 24 hours of each other.
- Beta blockers (propranolol): Propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
- Peripheral and central vasoconstrictors: The combination may cause synergistic elevation of blood pressure. Use with BREKIYA is contraindicated.
- Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
- Selective serotonin reuptake inhibitors (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline): Weakness, hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists were co-administered with SSRIs.
Read the label’s full interactions text
7 DRUG INTERACTIONS Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction. ( 7.3 , 7.5 ) Selective Serotonin Reuptake Inhibitors: Weakness, hyperreflexia, and incoordination may occur with coadministration. ( 7.6 ) 7.1 CYP3A4 Inhibitors There have been rare reports of serious adverse events in connection with the coadministration of intravenous administration of dihydroergotamine and strong CYP3A4 inhibitors resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities [see Warnings and Precautions (5.1) ]. The use of strong CYP3A4 inhibitors with BREKIYA is contraindicated [see Contraindications (4) ]. Administer moderate CYP3A4 inhibitors with caution. 7.2 Triptans Triptans (serotonin [5-HT 1B/1D receptor agonists) have been reported to cause coronary artery vasospasm, and its effect could be additive with BREKIYA. Therefore, triptans and BREKIYA should not be taken within 24 hours of each other [see Contraindications (4) ]. 7.3 Beta Blockers There have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. 7.4 Vasoconstrictors BREKIYA is contraindicated for use with peripheral and central vasoconstrictors because the combination may cause synergistic elevation of blood pressure [see Warnings and Precautions (5.5) ]. 7.5 Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy [see Warnings and Precautions (5.4) ] . 7.6 Selective Serotonin Reuptake Inhibitors Weakness, hyperreflexia, and incoordination have been reported rarely when 5-HT 1 agonists have been co-administered with selective serotonin reuptake inhibitors (SSRI’s) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline).
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Dihydroergotamine Injection
▾
- Do not use with heart disease, angina, past heart attack, or coronary artery spasm.
- Do not use with uncontrolled high blood pressure, peripheral arterial disease, sepsis, or after vascular surgery.
- Do not use with severe liver or kidney impairment.
- Do not use with ergot or latex allergy (Brekiya).
- A heart check is recommended first. People with risk factors should have the first dose in a medical setting.
- Avoid in pregnancy.
- Do not breastfeed during treatment and for 3 days after the last dose.
- Not established for children.
- Older adults need cautious dosing.
Dihydroergotamine Injection overdose
▾
Too much dihydroergotamine can cause ergotism, which means blood vessel spasm with numbness, tingling, pain, and bluish discoloration of the hands and feet. Other signs may include blood pressure changes, confusion, seizures, and nausea. Treatment includes stopping the drug, warming the affected area, vasodilators, and care to protect tissue. Contact a Poison Control Center or seek emergency care.
What Dihydroergotamine Injection does in the body
▾
Dihydroergotamine can raise blood pressure significantly, even in people with no history of high blood pressure. It also has oxytocic properties, meaning it can stimulate the uterus.
How your body processes Dihydroergotamine Injection
▾
Absorption from subcutaneous and intramuscular injection appeared similar, and it is poorly absorbed by mouth. About 93% of the drug is bound to proteins in the blood. It is mostly cleared by the liver and eliminated through bile in the feces, with only a small amount in urine. After intramuscular or intravenous use, the terminal half-life is about 9 hours.
How to store Dihydroergotamine Injection
▾
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) . Do not refrigerate or freeze.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Dihydroergotamine Injection
156 supplements and herbal products have documented interactions with Dihydroergotamine Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 4
- Moderate · 110
- Minor · 42
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Dihydroergotamine Injection: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Dihydroergotamine Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is this injection for?
▾
How do I use Brekiya?
▾
What side effects should I expect?
▾
What medicines should I avoid with it?
▾
Can I use it if I'm pregnant or breastfeeding?
▾
Why might I need a heart check first?
▾
Is Dihydroergotamine Injection available over the counter?
▾
When was Dihydroergotamine Injection first available?
▾
Who makes Dihydroergotamine Injection?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Dihydroergotamine Injection on HelloPharmacist
Dihydroergotamine Injection forms and strengths (how it comes)
Dihydroergotamine Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Dihydroergotamine Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Brekiya is used for acute treatment of migraine with or without aura in adults.
- Brekiya is used for acute treatment of cluster headaches in adults.
- Brekiya is not for migraine prevention, hemiplegic migraine, or migraine with brainstem aura.
- Brekiya is a prefilled single-dose autoinjector for subcutaneous injection only, into the middle thigh.
- Brekiya injection sites should be rotated and kept away from moles, scars, or tender, bruised, red, or hard skin.
- Brekiya should be used only if the liquid is clear and colorless.
Dihydroergotamine Injection on the U.S. market: products, makers and brands
How Dihydroergotamine Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
6 companies list 7 Dihydroergotamine Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1946. Brand names on the directory include DHE-45 Injection, Trudhesa, Atzumi and 2 more; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Dihydroergotamine Injection is used (Medicaid data)
A general measure of how commonly Dihydroergotamine Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Dihydroergotamine Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Dihydroergotamine Injection prescribed? Of the 1,601 medications we measure, Dihydroergotamine Injection ranks #1,447 by Medicaid prescriptions — more than 10% of them.
Utilization by Dihydroergotamine Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
1 ML dihydroergotamine mesylate 1 MG/ML Injection
Summed across the 3 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 861672
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Dihydroergotamine Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 3 of 19 listed Dihydroergotamine Injection NDCs with Medicaid activity.
Compare Dihydroergotamine Injection products
A representative set of FDA-listed product records for Dihydroergotamine Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 1 mg/mL | Subcutaneous | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Baxter Healthcare Corporation | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Hikma Pharmaceuticals USA Inc. × 2 listings | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Milla Pharmaceuticals Inc. | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Provepharm Inc. | ANDA | View NDC → |
Showing 7 of 7 products — FDA National Drug Code Directory. See every product, package size and price: browse all 7 Dihydroergotamine Injection NDCs →
Dihydroergotamine Injection side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Dihydroergotamine Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Dihydroergotamine Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Dihydroergotamine Injection FDA approval history
How Dihydroergotamine Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Dihydroergotamine Injection recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list one Dihydroergotamine recall since July 2021. It is still ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Dihydroergotamine Mesylate Injection, solution for injection, USP, 1 mg/mL Ampules, Rx Only, Distributed by: Provepharm Inc. 100 Springhouse Drive Suite 105, Collegeville, PA 19426, NDC 81284-411-05 Lots: Lot #: F9026F01, F9026F02, Exp. Date 12/2025 FDA record D-0150-2025 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 3418 6 dose forms · 8 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2714306In current FDA listingsClinical drug / strength (SCD) 1 ML dihydroergotamine mesylate 1 MG/MLRxCUI 2714308 -
Dose form (SCDF) Injection RxCUI 1860094In current FDA listingsClinical drug / strength (SCD) 1 ML dihydroergotamine mesylate 1 MG/MLRxCUI 861672 -
Dose form (SCDF) Metered Dose Nasal Spray RxCUI 2201618No current FDA listingClinical drug / strength (SCD) mesylate 0.5 MG/ACTUATRxCUI 861668mesylate 0.725 MG/ACTUATRxCUI 2569836 -
Dose form (SCDF) Nasal Powder RxCUI 2714186No current FDA listingClinical drug / strength (SCD) 5.2 MGRxCUI 2714187 -
Dose form (SCDF) Oral Tablet RxCUI 371844No current FDA listingClinical drug / strength (SCD) mesylate 1 MGRxCUI 1233876 -
Dose form (SCDF) Sublingual Tablet RxCUI 608727No current FDA listingClinical drug / strength (SCD) mesylate 0.5 MGRxCUI 1233874mesylate 1 MGRxCUI 1233880
Look up RxCUI 3418 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Dihydroergotamine Injection supply and shortage status
Whether Dihydroergotamine Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Dihydroergotamine Injection brand names
Dihydroergotamine Injection is sold under 5 brand names in the FDA directory — DHE-45 Injection, Trudhesa, Atzumi, Brekiya and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Dihydroergotamine Injection: manufacturers and labelers
6 companies list Dihydroergotamine Injection products with the FDA. By number of product records, the largest are Hikma Pharmaceuticals USA Inc., Amneal Pharmaceuticals LLC, Baxter Healthcare Corporation. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Dihydroergotamine Injection drug class (RxNorm)
Dihydroergotamine Injection belongs to the Ergotamine Derivative class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Dihydroergotamine Injection page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Amneal Pharmaceuticals LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →